Nycomed/Takeda Adds Antihistamine to China Portfolio

Nycomed, the Swiss biopharma being acquired by Takeda, has bought China marketing rights of an antihistamine from Almirall SA of Spain. Kestine is a member of the ebastine class of H1 inhibitors that do not cause drowsiness in users. At the same time, Takeda announced the closing of its $13 billion takeover of Nycomed, giving Takeda increased access to emerging markets such as China. More details.... Stock Symbols: (TSE: 4502) (BMAD: ALM) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});